- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Syncor to distribute PerImmune MoAb
Radiopharmacy firm Syncor International of Woodland Hills, CA, has signed an agreement for worldwide distribution of monoclonal antibody-based imaging and therapy agents under development by PerImmune of Rockville, MD. The deal includes HumaSPECT/CR, a
Radiopharmacy firm Syncor International of Woodland Hills, CA, has signed an agreement for worldwide distribution of monoclonal antibody-based imaging and therapy agents under development by PerImmune of Rockville, MD. The deal includes HumaSPECT/CR, a human monoclonal antibody for the diagnosis and staging of colorectal cancer that PerImmune is developing. Syncor also announced that it has completed its acquisition of the iodine-123 business of Golden Pharmaceuticals of Golden, CO (SCAN 2/19/97).
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
